Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Andrew DeRyke

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
International Journal of Antimicrobial Agents|June 24, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Wei-Ting Chen, et al.
Jac-Antimicrobial Resistance|June 30, 2023
Susceptibility profile and β-lactamase content of global <i>Pseudomonas aeruginosa</i> isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21James A Karlowsky, Sibylle H Lob, Mark A Estabrook, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 1, 2021
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018Michael A Pfaller, Dee Shortridge, Kelly A Harris, et al.
International Journal of Antimicrobial Agents|March 6, 2023
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Jac-Antimicrobial Resistance|January 25, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20James A Karlowsky, Sibylle H Lob, Brune Akrich, et al.
Journal of Medical Microbiology|February 10, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-<i>Morganellaceae Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
<i>In Vitro</i> Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Jac-Antimicrobial Resistance|July 5, 2021
Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICUPamela A Moise, Marcela Gonzalez, Irina Alekseeva, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 22, 2024
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021James A Karlowsky, Sibylle H Lob, Stephen P Hawser, et al.
Jac-Antimicrobial Resistance|August 14, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and <i>Pseudomonas aeruginosa</i> collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21James A Karlowsky, Sibylle H Lob, Stephen P Hawser, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
International Journal of Antimicrobial Agents|June 24, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Wei-Ting Chen, et al.
Jac-Antimicrobial Resistance|June 30, 2023
Susceptibility profile and β-lactamase content of global <i>Pseudomonas aeruginosa</i> isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21James A Karlowsky, Sibylle H Lob, Mark A Estabrook, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 1, 2021
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018Michael A Pfaller, Dee Shortridge, Kelly A Harris, et al.
International Journal of Antimicrobial Agents|March 6, 2023
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Jac-Antimicrobial Resistance|January 25, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20James A Karlowsky, Sibylle H Lob, Brune Akrich, et al.
Journal of Medical Microbiology|February 10, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-<i>Morganellaceae Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
<i>In Vitro</i> Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Jac-Antimicrobial Resistance|July 5, 2021
Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICUPamela A Moise, Marcela Gonzalez, Irina Alekseeva, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 22, 2024
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021James A Karlowsky, Sibylle H Lob, Stephen P Hawser, et al.
Jac-Antimicrobial Resistance|August 14, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and <i>Pseudomonas aeruginosa</i> collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21James A Karlowsky, Sibylle H Lob, Stephen P Hawser, et al.
Pageof 5